The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

At the American Society of Cell and Gene Therapy conference, there were questions and qualms on how Vinay Prasad may change ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to ...

For a brief period in 2022, Dr. Vinay Prasad faked a concern about routine vaccines to infect unvaccinated children with ...

The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual COVID-19 boosters for ...

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...

A hot (if cautious) topic at the big gene therapy meeting: what Vinay Prasad's appointment might mean for approvals in rare ...